Vivoryon Therapeutics N.V. new ISIN code
Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. new ISIN code
Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
HALLE (SAALE) / MUNICH, GERMANY, 29 January 2021 – the Board of Directors (Board) of Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that it will hold an Extraordinary General Meeting of Shareholders (EGM) on Friday, March 12, 2021. The EGM will take place virtually.
The EGM agenda, explanatory notes and terms of participation have been made public and are available as of January 29, 2021 on the Vivoryon website https://www.vivoryon.com/extraordinary-general-meeting-2021/. Vivoryon shareholders are invited to consult the company website in order to obtain current information on the procedures for participating in the EGM.
Key agenda items for the EGM include:
- Reappointment of Dr. Ulrich Dauer as executive member of the Board
The Board nominates Dr. Ulrich Dauer for reappointment as executive member of the Board and shall upon reappointment regrant him the title of Chief Executive Officer, effective May 1st, 2021.
- Appointment of Mr. Florian Schmid as executive member of the Board
The Board nominates Mr. Florian Schmid for appointment as executive member of the Board and shall upon appointment grant him the title of Chief Financial Officer, effective April 1st, 2021.
“I am delighted to welcome Florian Schmid to Vivoryon. He brings a wealth of experience to the Board, including an excellent track record in scaling organizations and leading finance and investor relations in the EU and US,” said Dr. Erich Platzer, Chairman of the Board.
Dr. Ulrich Dauer, CEO of Vivoryon, added: “Throughout his career, Florian has demonstrated remarkable talent in driving financial performance and serving as a strategic partner. We are convinced that Florian will be instrumental in executing our growth strategy and the development of our pipeline for the benefit of patients.”
“I am thrilled to join Vivoryon and to become a part of this ambitious team, which has dedicated itself to the fight against Alzheimer’s Disease,” said Florian Schmid. “Vivoryon is a prime example of an R&D-focused company that has successfully brought pharmaceutical innovation to patients in need. I look forward to contributing to Vivoryon’s further growth.”
Florian Schmid has twenty years of finance leadership experience in public biopharmaceutical and technology businesses. Mr. Schmid joins Vivoryon from InflaRx, where he served as Director Finance & Controlling supporting various financing transactions including a US IPO. Prior to that role,
Mr. Schmid spent nearly six years at T‐Systems International GmbH, where he most recently led the Global Deal & Business Support department. Mr. Schmid began his career as certified Tax Advisor and Public Accountant at Arthur Andersen and Ernst & Young. He received a business degree from the Ludwig‐Maximilian‐University, Munich. Mr. Schmid will lead all corporate finance functions as an executive member of the Board and will be based in Munich, Germany.
###
For more information, please contact:
Vivoryon Therapeutics N.V.
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com
Trophic Communications
Gretchen Schweitzer / Valeria Fisher
Tel: +49 172 861 8540 or +49 175 8041816
Email: vivoryon@trophic.eu
About Vivoryon Therapeutics N.V.
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer’s disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.